[Predictive factors of response to anthracyclines neoadjuvant chemotherapy in breast cancer].

Abstract

OBJECTIVES:

Anthracyclines chemotherapy remains primordial and impossible to circumvent in the treatment of breast cancer, in the adjuvant, metastatic and neoadjuvant setting. But some breast invasive tumors are resistant to anthracyclines. The neoadjuvant model is ideal to test the chemosensibility by selecting the well-responder patients and identifying the predictive factors of this response.

PATIENTS AND METHODS:

We report a retrospective study of 126 patients treated at our institute during 2 years (January 2003-December 2004) for a breast cancer with primary chemotherapy. All the patients received anthracyclines according to protocol AC60 (doxorubicine plus cyclophosphamide).

RESULTS:

The clinical objective response rate (RO) was 67 % with a complete clinical response (RC) of 11 %. We found a pathological complete response (pCR) in seven patients (5,6 %) of the 126 cases. The statistical study identifies only two clinical factors as predictive of RC and pCR: tumoral size T2-T3 and clinical nodal status N0-N1, while the SBR grading and the hormonal receptors were not correlated.

DISCUSSION AND CONCLUSION:

Some clinical and histological factors are recognized as predictive for the benefit of anthracyclines neoadjuvant chemotherapy, and correlated to the pCR; we discuss our results through those of the literature, by exposing the current data.

• Authors: Y Bensouda, N Ismaili, N Ahbeddou, K El Hassani, M Chenna, Y Sbitti, S Boutayeb, H Errihani
• Journal: Gynecologie, obstetrique & fertilite (Gynecol Obstet Fertil) Vol. 39 Issue 2 Pg. 81-6 (Feb 2011) ISSN: 1769-6682 [Electronic] France
• Vernacular Title: Chimiothérapie néoadjuvante par anthracyclines dans le cancer du sein : facteurs prédictifs de réponse.
• PMID: 21324724 (Publication Type: English Abstract, Journal Article)
• Copyright: Copyright © 2010 Elsevier Masson SAS. All rights reserved.

Chemical References

• Anthracyclines
• Doxorubicin
• Cyclophosphamide

Topics

• Adult
• Aged
• Anthracyclines (administration & dosage, therapeutic use)
• Breast Neoplasms (drug therapy, pathology)
• Cyclophosphamide (administration & dosage)
• Doxorubicin (administration & dosage)
• Drug Resistance, Neoplasm
• Female
• Humans
• Lymph Nodes (pathology)
• Middle Aged
• Neoadjuvant Therapy
• Neoplasm Invasiveness
• Retrospective Studies
• Treatment Outcome